Management of Patients With High Baseline Hip Fracture Risk by FRAX Reduces Hip Fractures-A Post Hoc Analysis of the SCOOP Study

Screening in the community to reduce fractures in older women (SCOOP): a randomised controlled trial

(2018) Lee Shepstone et al.   LANCET

The Effect of Abaloparatide-SC on Fracture Risk Is Independent of Baseline FRAX Fracture Probability: A Post Hoc Analysis of the ACTIVE Study

(2017) Eugene V McCloskey et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Identification and management of patients at increased risk of osteoporotic fracture: outcomes of an ESCEO expert consensus meeting

(2017) J. A. Kanis et al.   OSTEOPOROSIS INTERNATIONAL

Mind the (treatment) gap: a global perspective on current and future strategies for prevention of fragility fractures

(2017) N. C. W. Harvey et al.   OSTEOPOROSIS INTERNATIONAL

UK clinical guideline for the prevention and treatment of osteoporosis

(2017) J. Compston et al.   Archives of Osteoporosis

A systematic review of intervention thresholds based on FRAX

(2016) John A. Kanis et al.   Archives of Osteoporosis

A BMD threshold for treatment efficacy in osteoporosis? A need to consider the whole evidence base

(2015) E. McCloskey   OSTEOPOROSIS INTERNATIONAL

FRAX and the effect of teriparatide on vertebral and non-vertebral fracture

(2015) N. C. Harvey et al.   OSTEOPOROSIS INTERNATIONAL

Efficacy of weekly teriparatide does not vary by baseline fracture probability calculated using FRAX

(2015) N. C. Harvey et al.   OSTEOPOROSIS INTERNATIONAL

Denosumab reduces the risk of osteoporotic fractures in postmenopausal women, particularly in those with moderate to high fracture risk as assessed with FRAX

(2012) Eugene V McCloskey et al.   JOURNAL OF BONE AND MINERAL RESEARCH

A pragmatic randomised controlled trial of the effectiveness and cost-effectiveness of screening older women for the prevention of fractures: rationale, design and methods for the SCOOP study

(2012) L. Shepstone et al.   OSTEOPOROSIS INTERNATIONAL

Acceptability of screening to prevent osteoporotic fractures: a qualitative study with older women

(2011) C. L. Emmett et al.   FAMILY PRACTICE

A meta-analysis of the effect of strontium ranelate on the risk of vertebral and non-vertebral fracture in postmenopausal osteoporosis and the interaction with FRAX®

(2011) J. A. Kanis et al.   OSTEOPOROSIS INTERNATIONAL

A meta-analysis of the efficacy of raloxifene on all clinical and vertebral fractures and its dependency on FRAX®

(2010) John A. Kanis et al.   BONE

Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAX®

(2009) John A. Kanis et al.   BONE

Ten-year fracture probability identifies women who will benefit from clodronate therapy—additional results from a double-blind, placebo-controlled randomised study

(2008) E. V. McCloskey et al.   OSTEOPOROSIS INTERNATIONAL

FRAX™ and the assessment of fracture probability in men and women from the UK

(2008) J. A. Kanis et al.   OSTEOPOROSIS INTERNATIONAL